- Home
- Solutions
- By Services
- Diagnostics Development Services
As a research services provider, Protheragen understands the critical importance of early and accurate detection of ophthalmic diseases in driving the development of innovative therapeutics. We are committed to providing our customers with a one-stop ophthalmic disease therapy development service.
The development of diagnostics for ophthalmic diseases involves a comprehensive journey of researching, evaluating, and validating diagnostic tools, biomarkers, and imaging methods for eye-related conditions. This intricate process entails leveraging state-of-the-art technologies, creating pertinent animal models, and meticulously assessing diagnostic efficacy to seamlessly transition innovative solutions from the lab to clinical settings.
Fig.1 Ophthalmic technologies for ocular disease diagnostics. (Shi Y., et al., 2021)The foundation of ophthalmic diagnostics development rests upon delving into the intricate biology of the eye and the ailments that impact it. This encompasses exploring ocular anatomy, visual physiology, and the immunological reactions linked to different eye conditions. Profound expertise in molecular biology, genetics, and bioinformatics plays a pivotal role in crafting diagnostic assays capable of identifying particular biomarkers, genetic mutations, and disease indicators.
Molecular Diagnostics
Molecular diagnostics are pivotal in the advancement of ophthalmic diseases diagnostics. Innovations like polymerase chain reaction (PCR) and next-generation sequencing (NGS) enable the identification of precise genetic mutations linked to hereditary eye disorders. These cutting-edge technologies have transformed the landscape of diagnosing conditions such as retinitis pigmentosa and Leber's congenital amaurosis.
Imaging Technologies
Advanced imaging technologies are essential in ophthalmic diagnostics. Optical coherence tomography (OCT) provides high-resolution cross-sectional images of the retina, aiding in the diagnosis of conditions like macular degeneration and glaucoma. Fundus autofluorescence (FAF) imaging offers insights into retinal pigment epithelium dysfunction, particularly in diseases like age-related macular degeneration.
At Protheragen, we offer a comprehensive suite of services to support the development of cutting-edge ophthalmic disease diagnostics. Our specialized expertise encompasses the following key areas:
Genomics Analysis Services
Protheragen offers genomics analysis services, utilizing cutting-edge sequencing technologies to identify genetic mutations and variations associated with ophthalmic diseases. Our services include whole genome sequencing, targeted gene panels, and copy number variation analysis, providing comprehensive genetic profiles for researchers.
Biomarker Development Services
Biomarker development is a cornerstone of Protheragen's services. We focus on discovering and validating novel biomarkers for the diagnosis and prognosis of eye diseases. Our team of experts employs various techniques, including proteomics, genomics, and immunoassays, to identify potential biomarkers in ocular tissues and fluids.
Diagnostic Kit Development Services
Protheragen is committed to developing diagnostic kits that facilitate the rapid and accurate diagnosis of ophthalmic diseases. Our kits are designed for use in scientific studies with ease of use, high sensitivity and specificity. These kits encompass a range of tests, from molecular assays for genetic mutations to immunoassays for inflammatory markers.
Protheragen is committed to staying at the forefront of technological advancements, continuously investing in the latest diagnostic tools and analytical platforms to provide our clients with the most innovative solutions. If you are interested in our services, please feel free to contact us for more details and quotation information of related services.
References
Copyright © Protheragen. All rights reserved.